A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis

NCT01011322 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis
Large Intestine
Diarrhea
Abdominal Pain

Interventions

DRUG: LT-02
DRUG: placebo

Sponsor

Lipid Therapeutics GmbH